PE20241236A1 - Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina - Google Patents
Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatoninaInfo
- Publication number
- PE20241236A1 PE20241236A1 PE2024000480A PE2024000480A PE20241236A1 PE 20241236 A1 PE20241236 A1 PE 20241236A1 PE 2024000480 A PE2024000480 A PE 2024000480A PE 2024000480 A PE2024000480 A PE 2024000480A PE 20241236 A1 PE20241236 A1 PE 20241236A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- thc
- compound
- melatonin
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245799P | 2021-09-17 | 2021-09-17 | |
| PCT/US2022/076579 WO2023044433A1 (en) | 2021-09-17 | 2022-09-16 | Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241236A1 true PE20241236A1 (es) | 2024-06-19 |
Family
ID=83688895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000480A PE20241236A1 (es) | 2021-09-17 | 2022-09-16 | Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250275935A1 (https=) |
| EP (1) | EP4401717A1 (https=) |
| JP (1) | JP2024535871A (https=) |
| CA (1) | CA3232209A1 (https=) |
| CL (1) | CL2024000782A1 (https=) |
| CO (1) | CO2024004628A2 (https=) |
| PE (1) | PE20241236A1 (https=) |
| WO (1) | WO2023044433A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773527A4 (en) | 2018-03-30 | 2022-04-13 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR44305E (fr) | 1933-12-09 | 1934-12-24 | Meaf Mach En Apparaten Fab Nv | Circuits de voie à rails sans potentiel ou portés au même potentiel |
| US11065225B1 (en) | 2015-07-30 | 2021-07-20 | University Of South Florida | Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease |
| EP3538122B1 (en) * | 2016-11-14 | 2025-03-26 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
| EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | PREPARATIONS |
| WO2019036243A1 (en) * | 2017-08-16 | 2019-02-21 | Molecular Infusions, Llc | Formulations |
| US20200246404A1 (en) * | 2017-02-15 | 2020-08-06 | Molecular Infusions, Llc | Formulations |
| EP3773527A4 (en) | 2018-03-30 | 2022-04-13 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES |
| WO2021011421A1 (en) * | 2019-07-12 | 2021-01-21 | University Of South Florida | Compositions and methods for treating alzheimers disease |
-
2022
- 2022-09-16 EP EP22786718.1A patent/EP4401717A1/en active Pending
- 2022-09-16 CA CA3232209A patent/CA3232209A1/en active Pending
- 2022-09-16 US US18/692,705 patent/US20250275935A1/en active Pending
- 2022-09-16 WO PCT/US2022/076579 patent/WO2023044433A1/en not_active Ceased
- 2022-09-16 PE PE2024000480A patent/PE20241236A1/es unknown
- 2022-09-16 JP JP2024517078A patent/JP2024535871A/ja active Pending
-
2024
- 2024-03-15 CL CL2024000782A patent/CL2024000782A1/es unknown
- 2024-04-12 CO CONC2024/0004628A patent/CO2024004628A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023044433A1 (en) | 2023-03-23 |
| JP2024535871A (ja) | 2024-10-02 |
| CO2024004628A2 (es) | 2024-05-10 |
| US20250275935A1 (en) | 2025-09-04 |
| CA3232209A1 (en) | 2023-03-23 |
| EP4401717A1 (en) | 2024-07-24 |
| CL2024000782A1 (es) | 2024-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farokhnia et al. | N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study | |
| CL2021003452A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades. | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
| MX2021015499A (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades. | |
| CR20220250A (es) | Métodos para el tratamiento de trastornos depresivos | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| MX2022014199A (es) | Usos y formulaciones de los cannabinoides. | |
| BR112015029897A2 (pt) | composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição | |
| CL2023001580A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
| PE20241236A1 (es) | Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina | |
| EP2424536A4 (en) | NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| CO2024013759A2 (es) | Composición que comprende n-acetilcisteína, vitamina d y preferentemente glutatión, usos de la misma, y composiciones farmacéuticas y nutracéuticas de los mismos | |
| MX2023007510A (es) | Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades. | |
| EA028540B1 (ru) | Применение адсорбированного гомогената трутневого расплода и витамина dили витаминов группы d и/или их активных метаболитов для профилактики и лечения вирусных заболеваний | |
| Kumar | Neurotherapeutic Potential of Withania somnifera: Insights from Ayurvedic Medicine | |
| MX2022002451A (es) | Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos. | |
| Bano et al. | Effectiveness of melatonin supplementation in preventing cognitive decline among older adults with sleep disorders: a narrative review | |
| Cosentino et al. | New approach for treatment of radiotherapy-induced peripheral neuropathy: a pilot observational study | |
| CN111315238A (zh) | 用于减轻由衰老引起的女性病症的补充剂 | |
| MX2025012013A (es) | Protac de irak4 |